登录新浪财经APP 搜索【信披】查看更多考评等级 近日，*ST沪科公告披露收到中国证监会《立案告知书》。公告显示，因涉嫌信息披露违法违规，根据 相关法律法规，中国证监会决定对上海宽频科技股份有限公司立案。"目前，公司各项生产经营活动正 常有序开展，上述事项不会对公司经营和管理造成重大影响。"*ST沪科称。*ST沪科投资者维权征集正 在进行中，符合条件的投资者可报名维权(详见文末)。 *ST沪科全名即上海宽频科技股份有限公司，主营业务是塑料粒子的商品贸易，兼营有色金属、食用农 产品及生产生活物资等。公司的主要产品是化工产品、农产品。 就在此次被立案消息披露不久前，*ST沪科有高管离职。据公司12月2日公告，公司董事会近日收到董 事、董事会秘书兼财务负责人云峰的书面辞职报告，云峰因个人身体原因，申请辞去公司董事、董事会 秘书兼财务负责人及子公司相关职务。 值得一提的还有，半个多月前的11月28日，*ST沪科披露的一份非经营性资金占用事项的进展公告显 示，截至11月28日，*ST沪科原控股股东南京斯威特集团有限公司及其关联方违规占用上市公司资金余 额近3.49亿元，占最近一期经审计净资产的921.63%。 所需材料 ...

公告称，目前，公司各项生产经营活动正常有序开展，上述事项不会对公司经营和管理造成重大影响。 公司将积极配合中国证监会立案调查工作，并按照有关法律法规等规定和要求，及时做好信息披露。 2025年前三季度，*ST沪科共实现营业收入544.03万元，同比下降63.7%；实现归属于上市公司股东的净 利润为106.2万元，同比增长448.84%。 12月12日晚，*ST沪科发布公告称，公司收到中国证券监督管理委员会下发的《立案告知书》。因涉嫌 信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国 证券监督管理委员会决定对公司立案。 值得一提的是，*ST沪科于11月28日晚间对外披露关于非经营性资金占用事项的进展公告。公告显示， 截至公告披露日，公司原控股股东南京斯威特集团有限公司及其关联方违规占用上市公司资金余额约为 3.49亿元，占最近一期经审计净资产的921.63%。公司拟通过公开挂牌转让所持有的南京斯威特集团及 其关联公司因历史遗留问题产生的全部债权及其他或有债权，同时解除公司全部或有负债。上述事项尚 需通过国资委备案、董事会、股东大会审议批准，并以公开挂牌转让方式实施，能否 ...

Core Viewpoint - *ST HuKe is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, which adds to the company's existing delisting risk [2][4]. Group 1: Company Status - As of December 12, *ST HuKe's stock price was 3.81 yuan, with a market capitalization of 1.253 billion yuan, reflecting a decline of 0.26% [4]. - The company has been facing delisting risks since April 30, when its stock was flagged due to negative audited profit totals and revenues below 300 million yuan [6]. - The company reported a significant decline in operating scale, with revenues dropping from 367 million yuan in 2022 to 17 million yuan in 2024 [4][6]. Group 2: Financial Performance - The company is projected to incur continuous losses, with net profits of -22.015 million yuan in 2023 and -5.6828 million yuan in 2024 [4]. - For the first three quarters of 2025, *ST HuKe's revenue was only 5.4403 million yuan, representing a year-on-year decline of 63.70%, with a non-recurring net profit of -237,200 yuan [6]. - The decline in revenue is attributed to decreased income from both chemical and agricultural product trading, as well as increased contract penalties in the agricultural sector [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 投资快报记者 黄敏 广州报道 突发！12月12日晚间，上海宽频科技股份有限公司（*ST沪科，600608）公告称，公司于2025年12月12 日收到中国证券监督管理委员会下发的《立案告知书》。因涉嫌信息披露违法违规，根据《中华人民共 和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证券监督管理委员会决定对公司立案。 公告称，目前，公司各项生产经营活动正常有序开展，上述事项不会对公司经营和管理造成重大影响。 公司将积极配合中国证券监督管理委员会立案调查工作，并按照有关法律法规等规定和要求，及时做好 信息披露工作。敬请广大投资者注意投资风险。 据了解，*ST沪科主营业务以农产品、化工产品等产品的商品贸易为主，根据中国证监会《上市公司行 业分类指引》（2012年修订），公司所处行业属于"F51批发业"。2025年上半年公司农产品业务以鲜切 花和酒粮类产品为主，化工产品以钛白粉产品为主。 事实上，*ST沪科基本面并不乐观，此次涉嫌信披违规被立案调查可谓"雪上加霜"。该公司2025年三季 报显示，公司第三季度营收为104万元，同比降56.95%；归属于上市公司的 ...

Mergers and Acquisitions - *ST Bosen has terminated the plan to sell 35% equity of Shaanxi Bosen due to failure to reach agreement on key terms [1] - Chongqing Water intends to acquire wastewater treatment project assets for 382 million yuan [2] - Rongbai Technology plans to use 342 million yuan to acquire 54.9688% of Guizhou Xinren and will increase its capital by 140 million yuan [3] - Greeenmei intends to acquire 16.38% equity of Henan Recycling Group for 400 million yuan [4] Shareholding Changes - Xilong Science's major shareholder plans to reduce holdings by up to 1% [5] - Dream Lily's major shareholder intends to reduce holdings by up to 1% [6] - Jincheng Co., Ltd. plans to reduce holdings by up to 0.97% [7] Risk Matters - Bestme's actual controller has been released on bail [8] - Chaoxun Communication received a warning letter from Guangdong Securities Regulatory Commission for various issues [9] - *ST Huke has been filed for suspected violations of information disclosure [10]

Core Viewpoint - *ST沪科 has received a notice of investigation from the China Securities Regulatory Commission (CSRC) due to suspected violations of information disclosure laws, which the company claims will not significantly impact its operations and management [1][2]. Financial Performance - In the first three quarters of the year, *ST沪科 reported revenue of only 5.44 million, a year-on-year decline of 63.7%, while the net profit attributable to shareholders was 1.06 million, showing a significant increase [2]. - The company's revenue dropped sharply from 367 million in 2022 to 17.23 million in 2024, falling below 100 million [2]. - Continuous losses are expected for the years 2023 and 2024, with a risk of delisting if the total profit, net profit, or net profit after excluding non-recurring gains and losses is negative and revenue is below 300 million in 2025 [2]. Management Changes - Following the resignation of Yun Feng, the company’s board secretary and financial officer, the chairman Wang Tianyang is temporarily taking over the secretary duties, while financial manager Yang Xiuxin is acting as the financial officer [3]. - Yun Feng, who was appointed as a director in March 2024 and took on the roles of board secretary and financial officer in November, resigned due to personal health reasons after just over a year in these positions [3]. - Other significant management changes include the resignation of the chairman Zhang Lu in April and independent director Li Zheng in August, both citing personal reasons [3]. Shareholder Issues - The second-largest shareholder, Kunming Industrial Development Investment Co., Ltd., has had all its shares frozen, and the first-largest shareholder's shares are also under freeze [3]. - As of October, the former controlling shareholder, Nanjing Siweit Group Co., Ltd., and its affiliates had illegally occupied 349 million of the company's funds, accounting for 921.63% of the latest audited net assets [4].

今日焦点 恒瑞医药：HRS9531注射液临床试验获批准，针对MASH适应症全球暂无同类药物获批上市 恒瑞医药公告称，子公司福建盛迪医药有限公司收到国家药监局核准签发的HRS9531注射液的《药物临 床试验批准通知书》，将于近期开展临床试验。HRS9531注射液是具有全球自主知识产权的新型靶向抑 胃肽受体（GIPR）和胰高血糖素样肽-1受体（GLP-1R）的双激动剂，可在体内调节糖脂代谢、抑制食 欲和增强胰岛素敏感性，从而起到改善血糖和减轻体重的效果。对于代谢功能障碍相关脂肪性肝炎 （MASH）患者，HRS9531注射液有望通过改善肝脏脂质堆积、减轻炎症反应及潜在改善肝纤维化带来 综合获益。针对MASH适应症，全球范围内暂无同类药物获批上市。截至目前，HRS9531相关项目累计 研发投入约5.19亿元。 青岛港：终止现金收购油品公司100%股权及日照实华50%股权 2连板亚翔集成：股东EVER CREATIVE于12月11日减持41.4万股 亚翔集成公告称，公司股票于2025年12月11日、12月12日连续两个交易日内日收盘价格涨幅偏离值累计 超过20%，属于股票交易异常波动情形。公司于2025年9月2日披露了 ...

交易行情显示，12月12日，*ST沪科收跌0.26%，收于3.81元/股，总市值12.53亿元。 北京商报讯（记者 马换换 李佳雪）12月12日晚间，*ST沪科（600608）披露公告称，公司于当日收到 证监会下发的《立案告知书》，因涉嫌信息披露违法违规，证监会决定对公司立案。 *ST沪科表示，目前，公司各项生产经营活动正常有序开展，上述事项不会对公司经营和管理造成重大 影响。 ...

Group 1 - *ST Hu Ke received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected violations of information disclosure laws, leading to a formal case being opened against the company [2] - The company stated that its production and operational activities are currently normal and that the investigation will not have a significant impact on its management and operations [4] - The main business of *ST Hu Ke involves the trade of agricultural and chemical products, classified under "F51 Wholesale Industry" according to the CSRC [4] Group 2 - As of December 12, *ST Hu Ke's stock price was 3.81 yuan per share, with a total market capitalization of 1.253 billion yuan [5] - Humanwell Healthcare announced that it received an administrative penalty notice from the CSRC for failing to disclose non-operating fund occupation and related transactions in its annual reports, which contained significant omissions and false records [5] - Humanwell Healthcare's stock will be subject to risk warnings starting December 16, with a daily price fluctuation limit of 5% after being placed on the risk warning board [6] Group 3 - Humanwell Healthcare, established in 1993, is a leading pharmaceutical company in Hubei Province, with a strong presence in various therapeutic areas and a comprehensive pharmaceutical value chain [8] - As of December 12, Humanwell Healthcare's stock price was 18.15 yuan per share, with a total market capitalization of 29.625 billion yuan [9]

Group 1 - *ST Hu Ke announced on December 12, 2025, that it received a notice of investigation from the China Securities Regulatory Commission (CSRC) due to suspected violations of information disclosure laws [1][3] - The company stated that its production and operational activities are currently normal and that the investigation will not have a significant impact on its management [3] - The main business of *ST Hu Ke focuses on the trade of agricultural and chemical products, classified under "F51 Wholesale Industry" according to the CSRC [3] Group 2 - For the third quarter, *ST Hu Ke reported a revenue of 1.04 million yuan, a year-on-year decrease of 56.95%, with a net profit attributable to shareholders of 1.0271 million yuan [4] - As of December 12, 2025, *ST Hu Ke's stock price was 3.81 yuan per share, with a total market capitalization of 1.253 billion yuan [4] Group 3 - On the same day, Renfu Pharmaceutical announced it received a notice of administrative penalty from the CSRC for failing to disclose non-operating fund occupation and significant omissions in its annual reports for 2020 and 2022 [7] - Renfu Pharmaceutical's stock will be subject to risk warnings starting December 16, 2025, with a trading limit of 5% on price fluctuations [7][9] - The company, established in 1993, is a leading pharmaceutical enterprise in Hubei Province, focusing on a full industrial chain from intermediates to drug formulations [9] Group 4 - As of December 12, 2025, Renfu Pharmaceutical's stock price was 18.15 yuan per share, with a total market capitalization of 29.625 billion yuan [9]